Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Kína1/2. fázis

Efficacy and Safety of CAR-T Cells Therapy for Chronic or Refractory Primary Immune Thrombocytopenia (ITP)

A legfontosabb adatok

Ki végzi
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Hol
Kunming (Kína)A helyszín megnézése
Azonosító
Állapot
Toboroz
Fázis
1/2. fázis
Résztvevők
10 fő, tervezett
Kezdés
2024. febr. 1.
Várható befejezés
2027. dec. 31.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • CAR-T cells
A regiszteradat frissítve
2024. július 22.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for people with long-lasting or hard-to-treat primary immune thrombocytopenia (ITP), a disease with low platelets. Everyone gets CAR-T cell therapy.

Életkor
8 to 75 years
Nem
Men and women
A betegség stádiuma
Chronic ITP (lasting more than 12 months) or refractory ITP. Platelet count below 30 x 109 / L. No other disease that could cause low platelets.
Korábbi kezelés
Refractory means the first and second line standard ITP treatment did not work well enough or could not be tolerated. If taking corticosteroids, the dose must be stable for at least 2 weeks before screening.
Biomarker vagy leletérték
Platelet count <30 x 109 / L

A részvétel fő kizáró okai

  • Low platelets caused by another disease, or other bleeding or clotting disorders
  • Cancer now, or past chemotherapy or radiotherapy for cancer
  • Serious heart disease within one year, or a history of blood clots
  • HIV, active hepatitis B or C, or other serious active infections
  • Pregnancy or breastfeeding

A regiszter feltételei, szó szerint

Mind a 26 feltétel megnézéseKevesebb

Ki vehet részt

  • Willingness to complete the informed consent process and to comply with study procedures and visit schedule
  • Men and women aged 8-75
  • Participants diagnosed with chronic (>12 months duration) or refractory (a documented intolerance or insufficient response to the first and second line standard treatment of ITP) ITP
  • The results of physical, instrumental, and laboratory examination of patients not suggest any disease which may cause thrombocytopenia other than ITP
  • Platelet count <30 x 109 / L
  • If the patient is taking corticosteroids, the treatment regimen/dose should be stable (at least 2 weeks prior to screening)
  • The results of physical, instrumental, and laboratory examination of patients should be within the normal range or deviations should be regarded by the researcher as clinically insignificant
  • Willingness to use effective and reliable methods of contraception throughout the entire study period

Ki nem vehet részt

  • Grade III-IV heart failure or myocardial infarction, cardiac angioplasty or stenting, unstable angina pectoris, or other clinically prominent heart disease within one year prior to enrollment
  • Any other concomitant decompensated diseases or acute conditions, the presence of which, according to the researcher, may significantly affect the results of the study
  • Had undergone other clinical trials in the 4 weeks prior to participating in this trial
  • All subjects with diseases which may cause secondary immune thrombocytopenia
  • Hemostatic disorders other than chronic thrombocytopenia
  • Concurrent malignant disease and/or history of cancer treatment with cytotoxic chemotherapy and/or radiotherapy
  • History of thrombosis or presence of significant risk factors for thrombosis
  • Persons with acute or exacerbation of chronic diseases of the gastrointestinal tract associated with the risk of bleeding, acute infectious diseases, pathologies of the respiratory system
  • Human immunodeficiency virus (HIV) seropositivity, Hepatitis B surface antigen positive or hepatitis B core antibody positive and HBV-DNA positive, Patients with hepatitis C (HCV-RNA quantitative test results positive), Or the presence of other serious active viral or bacterial infections or uncontrolled systemic fungal infections
  • Patients with severe history of allergy or allergic constitution
  • History of mental illness and known alcohol/drug addiction
  • Subject treated with drugs that affect platelet function (including but not limited to aspirin, clopidogrel and/or NSAIDs) or anti-coagulants for > 3 consecutive days within 2 weeks of the study start and until the end of the study
  • History of platelet agglutination abnormality that prevents reliable measurement of platelet counts
  • Any clinically significant hepatic impairment (increase of serum transaminase levels by more than 3 times the upper limit of normal)
  • Serum creatinine levels are more than two times higher than the upper limit of normal for a given age and sex
  • Patients with preventive splenectomy
  • Pregnancy and lactation
  • Poor compliance due to physiological, family, social, geographical and other factors, unable to cooperate with the study protocol and follow-up plan

Nézd meg, megfelelhetsz-e

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 8 és 75 év között vagy?

Helyszínek itt: Kína

  • 920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaKunming, KínaContact: Sanbin Wang, DoctorRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

It is a single-center, single-arm, open-labeled clinical trial to evaluate the efficacy and safety of CAR-T cells therapy for Chronic or Refractory Primary Immune Thrombocytopenia (ITP).

A vizsgálat csoportja

  • CAR-T Cells TherapyA vizsgált kezelés

    Subjects who meet the enrollment conditions will receive intravenous infusion of CAR-T cells after lymphodepletion.

    Kezelés: CAR-T cells

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
An Investigator-initiated Trial to Evaluate the Efficacy and Safety of CAR-T Cells Therapy in the Treatment of Chronic or Refractory Primary Immune Thrombocytopenia (ITP)
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
Illeszkedési kérdések
Forrás: NCT06352281: ki vehet részt
A regiszteradat frissítve
2024. július 22.